Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tyrx antibacterial patch

This article was originally published in The Gray Sheet

Executive Summary

Firm gains FDA 510(k) clearance of its AIGISRx ST antibacterial soft tissue patch, intended for surgical repair of damaged or ruptured soft tissue, Tyrx announces April 27. The product delivers the antimicrobial agents rifampin and minocycline to ward off infections while reinforcing soft tissue where weakness exists. Tyrx currently markets AIGISRx Envelope and AIGISRx FS, with the same antibacterial technology, for use with cardiac pacemaker and defibrillator implants. The firm began enrollment of the 2,300-patient CITADEL prospective multicenter trial of its AIGISRx antibacterial mesh envelope on March 24 (1"The Gray Sheet" April 5, 2010)

You may also be interested in...



Financings In Brief

Sequenom stock offering grosses $96.6 million

Research In Brief

SynCardia heart portable driver: Company has received conditional IDE approval to begin a study of its Freedom portable driver to power the CardioWest total artificial heart in bridge-to-cardiac-transplant patients. The trial, which will enroll 60 subjects, aims to demonstrate that stable CardioWest patients can manage their portable driver outside the hospital. According to SynCardia, a "major drawback" of existing technology is that patients are attached to a 418-pound driver and confined to the hospital while they await transplant. By contrast, the Freedom driver weighs 13.5 pounds and would enable patients to resume normal activities while awaiting a transplant, the firm says. The study will follow patients until transplant, 90 days after discharge, 90 days of Freedom support in the hospital or death. The Freedom driver received CE mark approval for use in Europe March 1

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Topics

UsernamePublicRestriction

Register

MT028837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel